Top

Published in:

Open Access 01-03-2014 | Editorial

The Role of Health Economics and Outcomes Research in Health Care Reform in China

Authors: Wannian Liang, Jipan Xie, Hongpeng Fu, Eric Q. Wu

Published in: PharmacoEconomics | Issue 3/2014

Excerpt

The health care system in China has been undergoing reforms for the past three decades. New policies and regulations are being developed to better meet the health needs of over a billion people. As reform programs expand, the need for scientific evidence increases, to enable accurate evaluation of the impact of new policies. In this context, health economics and outcomes research (HEOR) will be instrumental to evidence-based decision making and is expected to play a major role in China’s health care reform. …

The Office of the Leading Group for Deepening the Reform of the Medical and Health Care System of the State Council. Q&A on deepening the medical and health care system reform [in Chinese]. Beijing: National Development and Reform Commission; 2009.

Ministry of Health. China public health statistical yearbook 2012 [in Chinese]. http://www.nhfpc.gov.cn/htmlfiles/zwgkzt/ptjnj/year2012/index2012.html. Accessed 25 Oct 2013.

Chen Z. Basic medical security systems cover 95% of the total population [in Chinese]. 2012 National Health Conference. 5 Jan 2012. http://money.163.com/12/0106/08/7N2Q8AN700253B0H.html. Accessed 25 Oct 2013.

Yang Q. 832 million people participate in NRCMS in China, participation rate exceeded 97%. The Ministry of Health press conference [in Chinese]. 27 Feb 2012. http://finance.chinanews.com/jk/2012/02-27/3700114.shtml. Accessed 25 Oct 2013.

Chen Z, Mao Z. Ending the subsidization of medical services with profits from the sales of medicines and deepening the reform of public hospitals. 8 Oct 2012. http://english.qstheory.cn/society/201210/t20121009_185287.htm. Accessed 13 Nov 2013.

General Office of the State Council. Notice of the General Office of the State Council on issuing the work arrangements for the reform of the medical and health care system in five key aspects [in Chinese]. Beijing: General Office of the State Council; 2010. http://www.gov.cn/zwgk/2010-04/19/content_1586732.htm. Accessed 25 Oct 2013.

People’s Daily Online. China issues new essential drug list. 16 Mar 2013. http://english.peopledaily.com.cn/90882/8170200.html. Accessed 13 Nov 2013.

National Health Development Research Center. Green book on China health development: research on healthcare reforms [in Chinese]. Beijing: People’s Medical Publishing House; 2013.

Manning WG, Newhouse JP, Duan N, et al. Health insurance and the demand for medical care: evidence from a randomized experiment. Am Econ Rev. 1987;77(3):251–77.PubMed

10.

Casalino LP, Nicholson S, Gans DN, et al. What does it cost physician practices to interact with health insurance plans? Health Aff (Millwood). 2009;28(4):w533–43.CrossRef

11.

Cutler DM, Sahni NR. If slow rate of health care spending growth persists, projections may be off by $770 billion. Health Aff (Millwood). 2013;32(5):841–50.CrossRef

12.

Morgan SG, McMahon M, Mitton C, et al. Centralized drug review processes in Australia, Canada, New Zealand, and the United Kingdom. Health Aff (Millwood). 2006;25(2):337–47.CrossRef

13.

Liu GG, Eggleston K, Hu T. Emerging health economics and outcomes research in the Asia-Pacific region. Value Health. 2008;11(Suppl 1):S1–2.PubMedCrossRef

14.

Liu G, Tang Y, Liu L. The urban employee medical insurance policy analysis: medical savings account and medical expenditures. Finance Econ. 2009;1(250):45–52.

15.

Langley PC, Mu R, Wu M, et al. The impact of rheumatoid arthritis on the burden of disease in urban China. J Med Econ. 2011;14(6):709–19.PubMedCrossRef

16.

Wang Y, Xu K, Hu H, et al. Prevalence, risk factors, and impact on health related quality of life of overactive bladder in China. Neurourol Urodyn. 2011;30(8):1448–55.PubMedCrossRef

17.

Wang R, Wu M, Ma X, et al. Body mass index and health-related quality of life in adults: a population based study in five cities in China. Eur J Public Health. 2012;22(4):497–502.PubMedCrossRef

18.

Jing S, Yin A, Shi L, Liu J. Whether New Cooperative Medical Schemes reduce the economic burden of chronic disease in rural China. PLoS One. 2013;8(1):e53062.PubMedCentralPubMedCrossRef

19.

Babiarz KS, Miller G, Yi H, et al. New evidence on the impact of China’s New Rural Cooperative Medical Scheme and its implications for rural primary healthcare: multivariate difference-in-difference analysis. BMJ. 2010;341:c5617.PubMedCrossRef

20.

Wang S, Peng L, Li J, et al. A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancer. PLoS One. 2013;8(3):e55917.PubMedCentralPubMedCrossRef

21.

Wu B, Ye M, Chen H, Shen JF. Costs of trastuzumab in combination with chemotherapy for HER2-positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context. Clin Ther. 2012;34(2):468–79.PubMedCrossRef

22.

Peking University, China Center for Health Economics Research. China guidelines for pharmacoeconomic evaluations, 9 Apr 2011. http://www.ispor.org/peguidelines/countrydet.asp?c=28&t=4. Accessed 25 Oct 2013.

23.

Wu EQ, Xie J, Wu C, Du EX, Li N, Tan R, et al. Treatment, monitoring, and economic outcomes of venous thromboembolism among hospitalized patients in China. PharmacoEconomics. 2014. doi:10.1007/s40273-014-0131-4

24.

Wang Y, Wang Y, Qain Y, Zhang J, Tang X, Sun J, Zhu D. Association of body mass index with cause specific deaths in Chinese elderly hypertensive patients: Minhang community study. PLoS One. 2013;8(8):e71223.PubMedCentralPubMedCrossRef

25.

Xue Q, Xiong X, Feng Y, Yao L, Chen S, Xiang L. Socioeconomic factors influencing anti psychotic prescription for schizophrenia inpatients in China: a cross-sectional study. Int Clin Psychopharmacol. Epub 2013 Dec 7.

26.

Wu EQ, Wu J, Yang HY, Zheng Y, Xie K, Yu R, Xie J. Economic burden of hepatocellular carcinoma in China. Presented at the ISPOR 17th Annual International Meeting poster session, Washington, DC, 2012 Jun 2–6.

27.

Xu J, Liu G, Deng G, Li L, Xiong X, Basu K. A comparison of outpatient healthcare expenditures between public and private medical institutions in urban China: an instrumental variable approach. Health Econ. Epub 2013 Dec 11.

28.

Chen G, Liu GG, Xu F. The impact of the urban resident basic medical insurance on health services utilisation in China. PharmacoEconomics. 2014. doi:10.1007/s40273-013-0097-7

29.

Chen M, Wang L, Chen W, Zhang L, Jiang H, Mao W. Does economic incentive matter for rational use of medicine? China’s experience from the essential medicines program. PharmacoEconomics. 2014. doi:10.1007/s40273-013-0068-z

30.

Wu J, Xu J, Liu GG, Wu J. Pharmaceutical pricing: an empirical study of market competition in Chinese hospitals. PharmacoEconomics. 2014. doi:10.1007/s40273-013-0099-5

31.

Shi L, Yang HY, Cheng G, Meng Q. Time trends and determinants of pharmaceutical expenditure in China (1990–2009). PharmacoEconomics. 2014. doi:10.1007/s40273-013-0072-3

32.

Yuan S, Liu Y, Li N, Zhang Y, Zhang Z, Tao J, et al. Impacts of health insurance benefit design on percutaneous coronary intervention use and inpatient costs among patients with acute myocardial infarction in Shanghai, China. PharmacoEconomics. 2014. doi:10.1007/s40273-013-0079-9

33.

Chongqing T, Liubao P, Xiaohui Z, Jianhe L, Xiaomin W, Gannong C, et al. Cost-utility analysis of the newly recommended adjuvant chemotherapy for resectable gastric cancer patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology: gastric cancer. PharmacoEconomics. 2014. doi:10.1007/s40273-013-0065-2

Title: The Role of Health Economics and Outcomes Research in Health Care Reform in China
Authors: Wannian Liang
Jipan Xie
Hongpeng Fu
Eric Q. Wu
Publication date: 01-03-2014
Publisher: Springer International Publishing
Published in: PharmacoEconomics / Issue 3/2014
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI: https://doi.org/10.1007/s40273-014-0141-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The Role of Health Economics and Outcomes Research in Health Care Reform in China

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2014

Impacts of Health Insurance Benefit Design on Percutaneous Coronary Intervention Use and Inpatient Costs among Patients with Acute Myocardial Infarction in Shanghai, China

Pharmaceutical Pricing: An Empirical Study of Market Competition in Chinese Hospitals

The Impact of the Urban Resident Basic Medical Insurance on Health Services Utilisation in China

Does Economic Incentive Matter for Rational Use of Medicine? China’s Experience from the Essential Medicines Program

Treatment, Monitoring, and Economic Outcomes of Venous Thromboembolism Among Hospitalized Patients in China

Cost–Utility Analysis of the Newly Recommended Adjuvant Chemotherapy for Resectable Gastric Cancer Patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Gastric Cancer